Income Statement

Currency: EUR

	Jun-2020	Dec-2020	Jun-2021	Sep-2021	Dec-2021	Jun-2022	Dec-2022	Jun-2023	Dec-2023	Jun-2024	Dec-2024	Jun-2025
Revenue
Interest Expense	0	0	0	0	0	0	0	0	0	0	0	0
Revenue	0 N/A	0 N/A	0 N/A	11 N/A	11 N/A	22 +100%	0 N/A	0 N/A	(4) N/A	(4) N/A	0 N/A	0 N/A
Gross Profit
Cost of Revenue	0	0	0	(0)	(2)	0	0	0	1	0	0	0
Gross Profit	0 N/A	0 N/A	0 N/A	10 N/A	9 -11%	0 N/A	0 N/A	0 N/A	(3) N/A	0 N/A	0 N/A	0 N/A
Operating Income
Operating Expenses	(12)	(16)	(20)	(25)	(22)	(31)	(29)	(26)	(26)	(28)	(21)	(13)
Selling, General & Administrative	(3)	(3)	(4)	(5)	(5)	(5)	(9)	(11)	(8)	(8)	(7)	(6)
Research & Development	(9)	(13)	(16)	(20)	(17)	(23)	(20)	(15)	(18)	(22)	(14)	(7)
Depreciation & Amortization	0	0	0	0	0	0	0	0	(0)	0	(0)	0
Other Operating Expenses	0	0	(0)	(0)	0	(2)	0	0	0	0	0	0
Operating Income	(12) N/A	(16) -32%	(20) -27%	(15) +26%	(13) +15%	(9) +29%	(29) -220%	(26) +9%	(29) -9%	(32) -11%	(21) +34%	(13) +39%
Pre-Tax Income
Interest Income Expense	(0)	(0)	(0)	(0)	1	1	1	(0)	0	1	0	0
Non-Reccuring Items	0	0	0	0	(0)	0	(0)	0	0	0	(0)	0
Total Other Income	0	0	(0)	0	0	0	0	0	0	0	0	0
Pre-Tax Income	(12) N/A	(17) -34%	(21) -25%	(15) +27%	(12) +19%	(8) +38%	(28) -275%	(27) +6%	(29) -7%	(31) -10%	(21) +34%	(12) +39%
Net Income
Tax Provision	0	0	0	(1)	(0)	(2)	0	0	0	0	0	0
Income from Continuing Operations	(12)	(17)	(21)	(16)	(13)	(9)	(28)	(26)	(28)	(31)	(21)	(12)
Net Income (Common)	(12) N/A	(17) -34%	(21) -25%	(16) +21%	(13) +22%	(9) +28%	(28) -207%	(26) +7%	(28) -8%	(31) -10%	(21) +34%	(12) +39%
EPS (Diluted)	-0.62 N/A	-0.83 -34%	-1.03 -24%	-0.81 +21%	-0.63 +22%	-0.43 +32%	-1.28 -198%	-1.01 +21%	-1.12 -11%	-1.19 -6%	-0.79 +34%	-0.48 +39%

Vivoryon Therapeutics NV
AEX:VVY